Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 749,465 |
|
|||||
| News | - | ||||||
| Day High | 5.62 | Low High |
|||||
| Day Low | 5.19 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| uniQure NV | QURE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.18 | -3.38% | 5.15 | 16:25:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.27 | 5.19 | 5.62 | 5.425 | 5.33 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,336 | 749,465 | $ 5.45 | $ 4,083,112 | - | 4.25 - 20.84 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:11:59 | formt | 1,000 | $ 5.15 | USD |
uniQure NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 260.24M | 47.84M | - | 21.9M | -308.48M | -6.45 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
uniQure NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QURE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.80 | 5.62 | 4.515 | 5.03 | 906,300 | 0.35 | 7.29% |
| 1 Month | 4.83 | 5.62 | 4.515 | 4.97 | 615,141 | 0.32 | 6.63% |
| 3 Months | 5.22 | 5.62 | 4.25 | 4.99 | 758,441 | -0.07 | -1.34% |
| 6 Months | 7.16 | 8.66 | 4.25 | 5.80 | 954,214 | -2.01 | -28.07% |
| 1 Year | 19.95 | 20.84 | 4.25 | 7.41 | 1,060,319 | -14.80 | -74.19% |
| 3 Years | 34.99 | 38.80 | 4.25 | 15.43 | 751,176 | -29.84 | -85.28% |
| 5 Years | 65.32 | 82.49 | 4.25 | 26.80 | 658,201 | -60.17 | -92.12% |
uniQure NV Description
| uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
